首页> 外文期刊>Molecular pharmacology. >Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth
【24h】

Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth

机译:小分子靶向增殖细胞核抗原染色质缔合抑制肿瘤细胞生长

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Proliferating cell nuclear antigen (PCNA), a potential anticancer target, forms a homotrimer and is required for DNA replication and numerous other cellular processes. The purpose of this study was to identify novel small molecules that modulate PCNA activity to affect tumor cell proliferation. An in silico screen of a compound library against a crystal structure of PCNA and a subsequent structural similarity search of the ZINC chemical database were carried out to derive relevant docking partners. Nine compounds, termed PCNA inhibitors (PCNA-Is), were selected for further characterization. PCNA-I1 selectively bound to PCNA trimers with a dissociation constant (K d) of ~0.2 to 0.4 μM. PCNA-Is promoted the formation of SDS-refractory PCNA trimers. PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells. Consistent with its effects on PCNA trimer stabilization, PCNA-I1 inhibited the growth of tumor cells of various tissue types with an IC50 of ~0.2 μM, whereas it affected the growth of nontransformed cells at significantly higher concentrations (IC 50, ~1.6 μM). Moreover, uptake of BrdU was dose-dependently reduced in cells treated with PCNA-I1. Mechanistically the PCNA-Is mimicked the effect of PCNA knockdown by siRNA, inducing cancer cell arrest at both the S and G 2/M phases. Thus, we have identified a class of compounds that can directly bind to PCNA, stabilize PCNA trimers, reduce PCNA association with chromatin, and inhibit tumor cell growth by inducing a cell cycle arrest. They are valuable tools in studying PCNA function and may be useful for future PCNA-targeted cancer therapy.
机译:增殖细胞核抗原(PCNA)是潜在的抗癌靶标,它形成同源三聚体,是DNA复制和许多其他细胞过程所必需的。这项研究的目的是确定调节PCNA活性以影响肿瘤细胞增殖的新型小分子。进行了针对PCNA晶体结构的化合物库的计算机模拟筛选,然后对ZINC化学数据库进行了结构相似性搜索,以得出相关的对接伴侣。选择了九种称为PCNA抑制剂(PCNA-Is)的化合物进行进一步表征。 PCNA-I1以〜0.2至0.4μM的解离常数(K d)选择性结合至PCNA三聚体。 PCNA-Is促进了耐SDS的PCNA三聚体的形成。 PCNA-11剂量和时间依赖性地减少细胞中与染色质相关的PCNA。与其对PCNA三聚体稳定作用相一致,PCNA-I1抑制各种组织类型的肿瘤细胞的生长,IC50为〜0.2μM,而以显着较高的浓度(IC 50,〜1.6μM)影响未转化细胞的生长。 。此外,在用PCNA-I1处理的细胞中,BrdU的摄取呈剂量依赖性降低。从机理上讲,PCNA-Is模仿了siRNA对PCNA的抑制作用,在S和G 2 / M期均诱导癌细胞停滞。因此,我们已经确定了一类可以直接结合PCNA,稳定PCNA三聚体,减少PCNA与染色质结合并通过诱导细胞周期停滞来抑制肿瘤细胞生长的化合物。它们是研究PCNA功能的有价值的工具,可能对将来针对PCNA的癌症治疗有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号